Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 200 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2002Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial FracturesCsimma, C.; Genant, H.; Valentin-Opran, A.; Amit, Y.; Arbel, R.; Aro, H.; Atar, D.; Bishay, M.; Borner, M.; Chiron, P.; Choong, P.; Cinats, J.; Courtenay, B.; Feibel, R.; Geulette, B.; Gravel, C.; Haas, N.; Raschke, M.; Hammacher, E.; van der Velde, D.; et al.
2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDruker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.
2016TBC1D24 genotype-phenotype correlationBalestrini, S.; Milh, M.; Castiglioni, C.; Lüthy, K.; Finelli, M.; Verstreken, P.; Cardon, A.; Stražišar, B.; Holder, J.; Lesca, G.; Mancardi, M.; Poulat, A.; Repetto, G.; Banka, S.; Bilo, L.; Birkeland, L.; Bosch, F.; Brockmann, K.; Cross, J.; Doummar, D.; et al.
2019Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction on Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) studyLioufas, N.; Toussaint, N.D.; Pedagogos, E.; Elder, G.; Badve, S.V.; Pascoe, E.; Valks, A.; Hawley, C.; Block, G.A.; Boudville, N.C.; Campbell, K.; Cameron, J.D.; Chen, S.S.M.; Faull, R.J.; Holt, S.G.; Hooi, L.S.; Jackson, D.; Jardine, M.J.; Johnson, D.W.; Kerr, P.G.; et al.
2020Plasma exchange and glucocorticoids in severe ANCA-associated vasculitisWalsh, M.; Merkel, P.A.; Peh, C.A.; Szpirt, W.M.; Puechal, X.; Fujimoto, S.; Hawley, C.M.; Khalidi, N.; Flosmann, O.; Wald, R.; Girard, L.P.; Levin, A.; Gregorini, G.; Harper, L.; Clark, W.F.; Pagnoux, C.; Specks, U.; Smyth, L.; Tesar, V.; Ito-Ihara, T.; et al.
2015Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancersOnengut-Gumuscu, S.; Chen, W.-M.; Burren, O.; Cooper, N.J.; Quinlan, A.R.; Mychaleckyj, J.C.; Farber, E.; Bonnie, J.K.; Szpak, M.; Schofield, E.; Achuthan, P.; Guo, H.; Fortune, M.D.; Stevens, H.; Walker, N.M.; Ward, L.D.; Kundaje, A.; Kellis, M.; Daly, M.J.; Barrett, J.C.; et al.
2018Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working GroupHibar, D.; Westlye, L.; Doan, N.; Jahanshad, N.; Cheung, J.; Ching, C.; Versace, A.; Bilderbeck, A.; Uhlmann, A.; Mwangi, B.; Krämer, B.; Overs, B.; Hartberg, C.; Abé, C.; Dima, D.; Grotegerd, D.; Sprooten, E.; Bøen, E.; Jimenez, E.; Howells, F.; et al.
2020Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trialTong, S.Y.C.; Lye, D.C.; Yahav, D.; Sud, A.; Robinson, J.O.; Nelson, J.; Archuleta, S.; Roberts, M.A.; Cass, A.; Paterson, D.L.; Foo, H.; Paul, M.; Guy, S.D.; Tramontana, A.R.; Walls, G.B.; McBride, S.; Bak, N.; Ghosh, N.; Rogers, B.A.; Ralph, A.P.; et al.
2021Subtype-specific differences in transmission cluster dynamics of HIV-1 B and CRF01_AE in New South Wales, AustraliaDi Giallonardo, F.; Pinto, A.N.; Keen, P.; Shaik, A.; Carrera, A.; Salem, H.; Selvey, C.; Nigro, S.J.; Fraser, N.; Price, K.; Holden, J.; Lee, F.J.; Dwyer, D.E.; Bavinton, B.R.; Geoghegan, J.L.; Grulich, A.E.; Kelleher, A.D.; Grulich, A.; Guy, R.; Prestage, G.; et al.
2023Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR TrialNegishi, T.; Thavendiranathan, P.; Penicka, M.; Lemieux, J.; Murbraech, K.; Miyazaki, S.; Shirazi, M.; Santoro, C.; Cho, G.Y.; Popescu, B.A.; Kosmala, W.; Costello, B.; la Gerche, A.; Mottram, P.; Thomas, L.; Seldrum, S.; Hristova, K.; Bansal, M.; Kurosawa, K.; Fukuda, N.; et al.